{"resourceType":"PlanDefinition","id":"coloRectal","meta":{"profile":["http://hl7.org.nz/fhir/StructureDefinition/CcaPlanDefinition"]},"extension":[{"extension":[{"url":"factor","valueCodeableConcept":{"coding":[{"code":"TOUPDATE-SUPPORT4","system":"http://snomed.info/sct","display":"Diarrhoea risk"}]}},{"url":"value","valueCodeableConcept":{"text":"low"}}],"url":"http://clinfhir.com/fhir/StructureDefinition/support-factor"},{"extension":[{"url":"factor","valueCodeableConcept":{"coding":[{"code":"TOUPDATE-SUPPORT8","system":"http://snomed.info/sct","display":"AntiFungal Prophylaxis"}]}},{"url":"value","valueCodeableConcept":{"text":"low"}}],"url":"http://clinfhir.com/fhir/StructureDefinition/support-factor"},{"extension":[{"url":"factor","valueCodeableConcept":{"coding":[{"code":"TOUPDATE-SUPPORT2","system":"http://snomed.info/sct","display":"Hypersensitivity / Infusion related reaction ris"}]}},{"url":"value","valueCodeableConcept":{"text":"low"}}],"url":"http://clinfhir.com/fhir/StructureDefinition/support-factor"}],"action":[{"action":[{"action":[{"action":[{"extension":[{"extension":[{"url":"day","valueInteger":1},{"url":"instructions","valueString":"Specific instructions for the first administration"}],"url":"http://clinfhir.com/fhir/StructureDefinition/timing-of-days"},{"extension":[{"url":"day","valueInteger":4},{"url":"instructions","valueString":"Specific instructions for the second administration"}],"url":"http://clinfhir.com/fhir/StructureDefinition/timing-of-days"}],"description":"2mg of Cabergoline daily on days 1 and 4 by IV Infusion over 20 minutes","definitionCanonical":"#act-cabergoline"},{"extension":[{"extension":[{"url":"day","valueInteger":2},{"url":"instructions","valueString":"Specific instructions for the first administration"}],"url":"http://clinfhir.com/fhir/StructureDefinition/timing-of-days"},{"extension":[{"url":"day","valueInteger":3},{"url":"instructions","valueString":"Specific instructions for the second administration"}],"url":"http://clinfhir.com/fhir/StructureDefinition/timing-of-days"},{"extension":[{"url":"day","valueInteger":4},{"url":"instructions","valueString":"Specific instructions for the third administration"}],"url":"http://clinfhir.com/fhir/StructureDefinition/timing-of-days"}],"definitionCanonical":"#act-tragacanth","description":"3mg of Tragacanth daily on days 2,3 and 4 by IV Infusion over 3 hours"}],"description":"Administration of Cabergoline and Tragacanth daily ","priority":"routine","timingTiming":{"repeat":{"count":4,"duration":14,"durationUnit":"d"}}}],"description":"Describes the single cycle in this regimen. Cycle length 14 days","selectionBehavior":"exactly-one"}],"description":"The first option for this regimen. There is only 1"}],"status":"draft","version":"3.0.3","title":"Colorectal Adjuvant FOLFOX (a7)","description":"A drug treatment regimen for Colorectal cancer","type":{"coding":[{"code":"clinical-protocol","system":"http://terminology.hl7.org/CodeSystem/plan-definition-type"}]},"publisher":"New Zealand Medicines Formulary LP","date":"2020-06-29T20:14:18.417+12:00","experimental":false,"contained":[{"resourceType":"ActivityDefinition","id":"ActTragacanth","meta":{"profile":["http://hl7.org.nz/fhir/StructureDefinition/CcaActivityDefinition"]},"text":{"div":"<div xmlns=\"http://www.w3.org/1999/xhtml\">Tragacanth administration, 3mg over 3 hours by continuous IV infusion</div>","status":"additional"},"productCodeableConcept":{"coding":[{"code":"10711851000116105","system":"https://nzulm.org.nz/nzmt","display":"Tragacanth"}]},"dosage":[{"text":"3 mg over 3 hours by IV infusion","route":{"coding":[{"code":"180177004","system":"http://snomed.info/sct","display":"continuous intravenous infusion"}]},"doseAndRate":[{"doseQuantity":{"value":3,"system":"http://unitsofmeasure.org","code":"mg"},"rateQuantity":{"value":3,"system":"http://unitsofmeasure.org","code":"h"}}]}],"status":"draft"}],"useContext":[{"code":{"code":"focus","system":"http://terminology.hl7.org/CodeSystem/usage-context-type"},"valueCodeableConcept":{"coding":[{"code":"781382000","system":"http://snomed.info/sct","display":"Colorectal cancer"}]}},{"code":{"code":"program","system":"http://terminology.hl7.org/CodeSystem/usage-context-type"},"valueCodeableConcept":{"coding":[{"code":"FOLFOX","system":"http://snomed.info/sct","display":"FOLFOX"}]}}],"relatedArtifact":[{"type":"citation","display":"test","url":"http://www.ncbi.nlm.nih.gov/pubmed/23434"},{"type":"citation","display":"test2","url":"http://www.ncbi.nlm.nih.gov/pubmed/34324"}],"text":{"status":"generated","div":"<div xmlns='http://www.w3.org/1999/xhtml'><div><h3>Colorectal Adjuvant FOLFOX (a7)</h3><p>A drug treatment regimen for Colorectal cancer</p><h4>Use Context</h4><div><strong>focus</strong>  Colorectal cancer http://snomed.info/sct 781382000</div><div><strong>program</strong>  FOLFOX http://snomed.info/sct FOLFOX</div><br/><h4>Support factors</h4><table class='table'><tr><th>Factor</th><th>Value</th></tr><tr><td>Diarrhoea risk</td><td>low</td></tr><tr><td>AntiFungal Prophylaxis</td><td>low</td></tr><tr><td>Hypersensitivity / Infusion related reaction ris</td><td>low</td></tr></table><br/><h4>Related artifacts</h4><table class='table'><tr><th>Type</th><th>Display</th><th>Url</th></tr><tr><td>citation</td><td>test</td><td>http://www.ncbi.nlm.nih.gov/pubmed/23434</td></tr><tr><td>citation</td><td>test2</td><td>http://www.ncbi.nlm.nih.gov/pubmed/34324</td></tr></table><br/><h4>Regimen details</h4><div>Cycle#0  Administration of Cabergoline and Tragacanth daily </div><div>Cycle length: 14 d Repeat:4 times</div><div>&nbsp;&nbsp;Action#0  2mg of Cabergoline daily on days 1 and 4 by IV Infusion over 20 minutes</div><div>&nbsp;&nbsp;&nbsp;&nbsp;Day#1  Specific instructions for the first administration</div><div>&nbsp;&nbsp;&nbsp;&nbsp;Day#4  Specific instructions for the second administration</div><div>&nbsp;&nbsp;Action#1  3mg of Tragacanth daily on days 2,3 and 4 by IV Infusion over 3 hours</div><div>&nbsp;&nbsp;&nbsp;&nbsp;Day#2  Specific instructions for the first administration</div><div>&nbsp;&nbsp;&nbsp;&nbsp;Day#3  Specific instructions for the second administration</div><div>&nbsp;&nbsp;&nbsp;&nbsp;Day#4  Specific instructions for the third administration</div></div></div>"}}